A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2002
10/17/2002	WO2002081027A1 An antioxidant composition and a cosmetic or pharmaceutical composition
10/17/2002	WO2002081020A2 Method for preventing acute renal failure
10/17/2002	WO2002080978A2 Pharmaceutical compositions comprising ascomycin
10/17/2002	WO2002080975A1 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
10/17/2002	WO2002080974A1 Novel medicinal use of cytokine production inhibitor
10/17/2002	WO2002080973A1 Composition for use in therapy of hard tissue of mammal and method of therapy thereof
10/17/2002	WO2002080971A1 Composition comprising an androgen receptor blocker and an insulin sensitizing agent and use thereof for treatment of polycystic ovary syndrome
10/17/2002	WO2002080962A1 Papaine containing pharmaceutical formulation resp. its use
10/17/2002	WO2002080960A2 Treatment of neuropathologies associated with expression of tnf-alpha
10/17/2002	WO2002080957A1 Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease
10/17/2002	WO2002080955A1 Stimulation of osteogenesis using rank ligand fusion proteins
10/17/2002	WO2002080952A2 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
10/17/2002	WO2002080946A1 Compositions for preventing and/or treating oral diseases
10/17/2002	WO2002080943A1 Zinc ionophores as anti-stress agents
10/17/2002	WO2002080942A1 Pharmaceutical composition comprising copper, salicyclic acid, vitamin c and zinc for use in treatment of different diseases such as bacterial or viral infection
10/17/2002	WO2002080941A1 Compositions for preparing external carbon dioxide agents
10/17/2002	WO2002080940A2 Pharmacologically active strong acid solutions
10/17/2002	WO2002080939A2 Ionene polymers and their use as antimicrobial agents
10/17/2002	WO2002080938A1 Use of sodium nucleospermate for treating aids and treatment method
10/17/2002	WO2002080937A1 Antineoplastic compositions comprising trk tyrosine kinase inhibitors and nucleotide analogs
10/17/2002	WO2002080936A1 Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
10/17/2002	WO2002080935A1 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
10/17/2002	WO2002080934A1 A composition comprising glucosamine for treating angiogenesis-dependent diseases
10/17/2002	WO2002080933A1 A drug for use in bone grafting
10/17/2002	WO2002080932A1 Methods of treating acne
10/17/2002	WO2002080930A1 Intermittent lowering of levels of cortisol and other adrenalhormones as treatment of clinical conditions associated with abnormal concentrations of such hormones in man and animals
10/17/2002	WO2002080929A1 Remedies or preventives for interstitial nephritis
10/17/2002	WO2002080928A1 N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
10/17/2002	WO2002080927A1 Use of selective cox-2 inhibitors for the treatment of urinary incontinence
10/17/2002	WO2002080926A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	WO2002080925A1 Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders
10/17/2002	WO2002080924A1 Novel use of arylethene sulfonamide derivative
10/17/2002	WO2002080923A1 Substances for use in therapy of diseases that are caused by highly proliferative cells
10/17/2002	WO2002080922A1 Method and composition for topical treatment of viral lesions
10/17/2002	WO2002080921A1 Composition for inhibiting hiv activity extracted from paecilomyces sp. (tochu-kaso) j300
10/17/2002	WO2002080919A1 Therapeutic compounds and methods
10/17/2002	WO2002080918A1 Remedial or prophylactic agent for frequent urination or urinary incontinence
10/17/2002	WO2002080917A1 Novel use of proton pump inhibitors
10/17/2002	WO2002080916A1 Composition and method for the treatment of respiratory disease
10/17/2002	WO2002080915A2 Composition for the treatment of night sight problems (halos, coma and glare) comprising aceclidine
10/17/2002	WO2002080914A2 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
10/17/2002	WO2002080913A1 Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth
10/17/2002	WO2002080912A1 Reconstitutable parenteral composition containing a cox-2 inhibitor
10/17/2002	WO2002080911A2 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments for the treatment of neurodegenerative diseases
10/17/2002	WO2002080910A1 Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
10/17/2002	WO2002080909A1 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
10/17/2002	WO2002080908A1 Azolylcarbynol derivatives of aryl (or heteroaryl) for the treatment of respiratory diseases
10/17/2002	WO2002080907A1 Combination of lactacystin analog and immunosuppressive drug for the prolongation of allograft survival
10/17/2002	WO2002080906A1 Prevention and treatment of endometriosis with aryl hydrocarbon receptor binding ligands
10/17/2002	WO2002080905A1 Kappa opiate agonists for the treatment of bladder diseases
10/17/2002	WO2002080904A1 Liver funcion protecting or ameliorating agent
10/17/2002	WO2002080903A1 Functional role for cannabinoids in autonomic stability during sleep
10/17/2002	WO2002080902A1 Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp
10/17/2002	WO2002080901A2 Method for the production of anhydrous, pharmaceutical formulations of xanthogenates
10/17/2002	WO2002080900A1 Method for improving the well-being of poultry by in-ovo injection of carnitine
10/17/2002	WO2002080899A1 Remedial agent for digestive disease
10/17/2002	WO2002080898A2 Methods for treating hyperactive gastric motility
10/17/2002	WO2002080897A1 Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
10/17/2002	WO2002080896A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors
10/17/2002	WO2002080895A2 Treatment of malaria with farsenyl protein transferase inhibitors
10/17/2002	WO2002080893A1 Treatment of low back pain and whiplash associated disorder
10/17/2002	WO2002080892A1 Use of tnf inhibitor for treatment of whiplash associated disorder
10/17/2002	WO2002080891A1 Use of a tnf inhibitor for the treatment of low back pain
10/17/2002	WO2002080890A2 A jasmonate pharmaceutical composition for treatment of cancer
10/17/2002	WO2002080889A2 A combination dosage of a cyclooxygenase (cox) inhibitor, a vitamin d3 including analogues and metabolites thereof and/or calcium for prevention of epithelial cancer
10/17/2002	WO2002080888A2 Estrogen receptor-related receptor alpha (err) agonist for inducing cartilage formation
10/17/2002	WO2002080887A2 Timed pulse release composition
10/17/2002	WO2002080884A2 Powder inhaler formulations
10/17/2002	WO2002080883A2 Method and composition for solubilising a biologically active compound with low water solubility
10/17/2002	WO2002080860A2 Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
10/17/2002	WO2002080859A2 Inhalation drug combinations
10/17/2002	WO2002080856A2 Triaza compound immunoregulatory agents
10/17/2002	WO2002080855A2 Methods and compounds for decreasing cell toxicity or death
10/17/2002	WO2002080854A2 Compositions and methods for the prevention and treatment of human prostate cancer
10/17/2002	WO2002080850A2 Bulking agents as satiety agents
10/17/2002	WO2002080842A2 Medicament and method for diagnosing an autoimmune condition_in particular psoriasis
10/17/2002	WO2002080678A1 Antifungal composition with enhanced bioavailability
10/17/2002	WO2002080669A2 Use of alpha2-adrenergic receptor agonists and adrenergic inhibitors in reducing defoliation
10/17/2002	WO2002080668A2 Antimicrobial formulations
10/17/2002	WO2002070524A3 N-but-3-enyl norbuprenorphine and its use as analgesic
10/17/2002	WO2002068414A3 Analogs of thalidomide as potential angiogenesis inhibitors
10/17/2002	WO2002067890A3 Method and product for skin lightening
10/17/2002	WO2002066468A3 Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
10/17/2002	WO2002066456A3 Thiophene substituted amine derivatives as glyt-1 inhibitors
10/17/2002	WO2002065991A3 Divalproex sodium tablets
10/17/2002	WO2002062301A3 Method and composition for rejuvinating cells, tissues, organs, hair and nails
10/17/2002	WO2002062260A3 Improved ophthalmic and contact lens solutions containing forms of vitamin b
10/17/2002	WO2002060341A3 Inhibition of proteasomes to prevent restenosis
10/17/2002	WO2002059114A9 Lfa-1 antagonist compounds
10/17/2002	WO2002057261A3 Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
10/17/2002	WO2002056834A3 Method for alleviating syndromes and conditions of discomfort of the mammalian intestinal and genito-urinary tracts
10/17/2002	WO2002049628A3 Methods of treating anxiety disorders
10/17/2002	WO2002049626A3 The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity
10/17/2002	WO2002047493A3 Health promoting compositions
10/17/2002	WO2002044156A3 Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
10/17/2002	WO2002043702A3 Pharmaceutical compositions for inhalation
10/17/2002	WO2002043701A3 Method of making particles for use in a pharmaceutical composition
10/17/2002	WO2002042292A3 Indol derivative and their use as inhibitors of p38 kinase
10/17/2002	WO2002041898A3 Antibacterial methods and screens
10/17/2002	WO2002041894A3 Selective dopamine d4 receptor agonists for treating sexual dysfunction

1 ... 5676 5677 5678 5679 5680 5681 5682 5683 5684 5685 5686 5687 5688 5689 5690 5691 5692 5693 5694 5695 5696 ... 7860